论文部分内容阅读
美国Chiron公司在本国开始其人免疫缺陷病毒( HIV)疫苗的临床试验。试验检测了新一代HIV疫苗,这种疫苗试图诱生细胞免疫应答及能中和病毒的广泛抗体应答。 期临床试验将评估疫苗的安全性和免疫原性。 接种策略包括先由DNA免疫诱导免疫应答,然后以寡聚体基因工程包膜蛋白来增
Chiron Corporation in the United States started its clinical trial of its human immunodeficiency virus (HIV) vaccine. The test detects a new generation of HIV vaccines that attempt to induce a cellular immune response and a broad antibody response that neutralizes the virus. Phase of clinical trials will assess the safety and immunogenicity of the vaccine. Vaccination strategies include first inducing an immune response by DNA immunization and then increasing with oligomeric, genetically engineered envelope proteins